Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...

As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Northeastern Chinese company 3SBio to receive $1.25B, in addition to $100M equity investment, $150M for exclusive rights in ...

3SBio also launched Cipterbin (inetetamab) in 2020 and was covered under the National Reimbursement Drug List, or NRDL, the same year. This is an analog of Roche’s anti-HER2 mAb Herceptin.

HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximately ...

3SBio has good financial health. As of 2020, total debt was CNY 3 billion, net debt was minus CNY 218 million, and net debt to equity was negative 2%. The company generates approximately CNY 1 ...

Pfizer secrued exclusive global rights to 3SBio's cancer treatment candidate. It is a a licensing deal that could be worth $6.05 billion.

The positions in the table below reflect the 3SBio's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position links to the ...

China-based biotechnology firm 3SBio Inc <SSRX.O> said an investor group led by its chief executive Jing Lou has offered to take the company private for up to $15 per American Depositary ...